ArticleESMO gastrointestinal oncology2026
Readministration of nivolumab for patients with advanced gastric cancer: a case series.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nivolumab (NIVO), an immune checkpoint inhibitor (ICI) combined with chemotherapy, represents the standard of care for patients with human epidermal growth factor receptor 2-negative advanced gastric cancer (AGC). Although ICI readministration either as a rechallenge following disease progression or as a reintroduction after refractory has demonstrated clinical benefit and safety in patients with lung cancer or melanoma, evidence in AGC remains limited. Patients and methods: This case series analyzed eight patients with AGC who received NIVO readministration monotherapy between September 2017 and December 2021. Results: Six patients transitioned after disease progression, while two patients discontinued initial NIVO due to grade 2 pneumonitis. Among six patients with NIVO rechallenge, median progression-free survival (PFS) after rechallenge was 1.8 months [95% confidence interval (CI) 0.6-19.3 months], and median overall survival (OS) was 17.9 months (95% CI 1.8-42 months). Two patients achieved stable disease. Patients with ascites, Eastern Cooperative Oncology Group performance status of 1, or bulky liver/peritoneal metastasis tended toward shorter PFS and OS. Among two patients with NIVO reintroduction, one patient experienced a grade 2 rash; however, neither patient developed pneumonitis. Conclusions: NIVO readministration may offer clinical benefit to selected patients with AGC, without inducing severe adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.